NKF(SH:603707)2019-11-13 07:46Group 1: Company Overview and Business Strategy - Jianyou Co., Ltd. focuses on heparin as its main business, integrating production, research and development, and sales, with a vision to establish an internationally leading pharmaceutical enterprise [2] - The company's business modules are divided into four segments: heparin raw materials, heparin preparations, generic drugs - sterile preparations, and CDMO (Contract Development and Manufacturing Organization) business [2] Group 2: Financial Performance and Market Position - Heparin raw material revenue has shown continuous growth from 2016 to June 2019, further consolidating the company's market position [3] - The heparin preparation business has maintained high-speed growth, with active expansion into foreign markets, including the submission of applications for various heparin sodium injection products in Europe, the USA, and Brazil [3] Group 3: CDMO Business Development - The CDMO business has seen continuous growth driven by product research and development capabilities, industrialization capabilities, and global market capabilities, with numerous collaborations with well-known pharmaceutical companies [3] - Since 2016, the number of approved applications for generic drug products has been steadily increasing, expanding the product line to meet market demand [3] Group 4: Market Insights and Future Prospects - Currently, China's heparin usage accounts for only 5% of the global total, indicating significant future growth potential as the per capita usage is only one-tenth of that in European countries [4] - The market for low molecular weight heparin is broad, with applications in various medical fields, including orthopedics, cardiovascular, and reproductive health, highlighting its safety compared to other anticoagulants [4]